0.11Open0.11Pre Close0 Volume479 Open Interest20.00Strike Price0.00Turnover269.24%IV68.99%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.11Extrinsic Value100Contract SizeAmericanOptions Type0.0729Delta0.0363Gamma108.18Leverage Ratio-0.0467Theta0.0001Rho7.89Eff Leverage0.0020Vega
ARS Pharmaceuticals Stock Discussion
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...
Reuters10/15/2024 13:04
ARS PHARMACEUTICALS- UNIT ENTERED SUPPLY AGREEMENT WITH NUOVA OMPI S.R.L. This is an Italian company and I’m assuming distribution in EU is in the near future 👏
3 MINUTES AGO, 4:47 PM EDT
VIA GLOBENEWSWIRE
If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children
The submission of neffy 1 mg sNDA follows FDA approval on August 9, 2024, of neffy (2 mg) for the treatment of Type I Allergic Reactions, i...
No comment yet